Literature DB >> 16434374

Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation.

Per Ljungman1, Lena Perez-Bercoff, Jerker Jonsson, Gayane Avetisyan, Elda Sparrelid, Johan Aschan, Lisbeth Barkholt, Kajsa Larsson, Jacek Winiarski, Zhibing Yun, Olle Ringdén.   

Abstract

BACKGROUND AND OBJECTIVES: Cytomegalovirus (CMV) disease remains an important complication of allogeneic stem cell transplantation (SCT). We studied viral load kinetics and correlated the viral load and other transplant factors with the development of CMV disease. DESIGN AND METHODS: We studied 162 consecutive patients who were CMV seropositive or had CMV seropositive donors. Quantification of CMV DNA was performed by real-time polymerase chain reaction.
RESULTS: CMV DNA detected was detected in 105 of the 162 patients. The mean peak viral loads were similar at first and subsequent reactivations. The serologic status of the donors and recipients prior to SCT significantly influenced the viral load. The cumulative incidence of CMV disease was 1.8% at 100 days and 6.3% at 365 days after SCT. The peak viral load were higher in patients who developed CMV disease than in patients without CMV disease (log10 3.5; SE +/- 0.26/200,000 cells vs. log10 2.7; SE +/- 0.09/200,000 cells; p=0.02). However, in multivariate analysis, only acute graft-versus-host disease (GVHD) grade II-IV and a graft from a CMV-negative donor to a CMV-positive patient were significant risk factors for CMV disease. In patients who required more than one course of pre-emptive therapy, acute GVHD and the rate of decrease in viral load during first pre-emptive therapy were significant risk factors for subsequent development of CMV disease. INTERPRETATION AND
CONCLUSIONS: A decrease in viral load during pre-emptive therapy is an important factor for later development of CMV disease.

Entities:  

Mesh:

Year:  2006        PMID: 16434374

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  68 in total

1.  Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.

Authors:  Margaret L Green; Wendy Leisenring; Daniel Stachel; Steven A Pergam; Brenda M Sandmaier; Anna Wald; Lawrence Corey; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-07       Impact factor: 5.742

2.  Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients.

Authors:  Bryan T Alexander; Lindsay M Hladnik; Kristan M Augustin; Ed Casabar; Peggy S McKinnon; Richard M Reichley; David J Ritchie; Peter Westervelt; Erik R Dubberke
Journal:  Pharmacotherapy       Date:  2010-06       Impact factor: 4.705

3.  Cytomegalovirus infection according to cell source after hematopoietic cell transplantation in pediatric patients.

Authors:  Eun Sang Yi; Yae-Jean Kim
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

Review 4.  How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh; Per Ljungman
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

5.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

6.  Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.

Authors:  Shivaprasad Manjappa; Pavan Kumar Bhamidipati; Keith E Stokerl-Goldstein; John F DiPersio; Geoffrey L Uy; Peter Westervelt; Jingxia Liu; Mark A Schroeder; Ravi Vij; Camille N Abboud; Todd A Fehniger; Amanda F Cashen; Iskra Pusic; Meagan Jacoby; Srinidhi J Meera; Rizwan Romee
Journal:  Biol Blood Marrow Transplant       Date:  2013-10-10       Impact factor: 5.742

7.  Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients.

Authors:  Filippo Milano; Steven A Pergam; Hu Xie; Wendy M Leisenring; Jonathan A Gutman; Ivy Riffkin; Victor Chow; Michael J Boeckh; Colleen Delaney
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

8.  Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation.

Authors:  Stéphane Buhler; Florence Bettens; Carole Dantin; Sylvie Ferrari-Lacraz; Marc Ansari; Anne-Claire Mamez; Stavroula Masouridi-Levrat; Yves Chalandon; Jean Villard
Journal:  Leukemia       Date:  2019-11-26       Impact factor: 11.528

9.  Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT.

Authors:  Angela P Campbell; Jason W Chien; Jane Kuypers; Janet A Englund; Anna Wald; Katherine A Guthrie; Lawrence Corey; Michael Boeckh
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

Review 10.  Preventing stem cell transplantation-associated viral infections using T-cell therapy.

Authors:  Ifigeneia Tzannou; Ann M Leen
Journal:  Immunotherapy       Date:  2015-08-07       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.